Patents by Inventor Fabien Barbirato

Fabien Barbirato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11970690
    Abstract: The present disclosure is directed to a method for cultivating a Bordetella species, comprising: cultivating a Bordetella species under aerobic conditions in a liquid culture medium; and maintaining a pH of the liquid culture medium by using a strong acid, such as nitric acid, or using a first and second acid, wherein the first acid is an inorganic acid that dissociates essentially completely in water, such as nitric acid, hydrochloric acid or sulfuric acid, and wherein the second acid is an inorganic acid having an acid dissociation constant (pKa) of greater than 1, such as phosphoric acid. Methods for increasing the yield of Bordetella fimbrial agglutinogen 2 and fimbrial agglutinogen 3 (FIM2/3) in a supernatant fraction from a Bordetella culture are also provided.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: April 30, 2024
    Assignee: SANOFI PASTEUR INC.
    Inventors: Patrick Farrell, Bo Zhi Sun, Fabien Barbirato, Javier de Jesus Menendez Diaz, Andrew Chiappetta
  • Publication number: 20200407678
    Abstract: The present disclosure is directed to a method for cultivating a Bordetella species, comprising: cultivating a Bordetella species under aerobic conditions in a liquid culture medium; and maintaining a pH of the liquid culture medium by using a strong acid, such as nitric acid, or using a first and second acid, wherein the first acid is an inorganic acid that dissociates essentially completely in water, such as nitric acid, hydrochloric acid or sulfuric acid, and wherein the second acid is an inorganic acid having an acid dissociation constant (pKa) of greater than 1, such as phosphoric acid. Methods for increasing the yield of Bordetella finbria agglutinogen 2 and fimbrial agglutinogen 3 (FIM2/3) in a supernatant fraction from a Bordetella culture are also provided.
    Type: Application
    Filed: March 19, 2019
    Publication date: December 31, 2020
    Inventors: Patrick FARRELL, Bo Zhi SUN, Fabien BARBIRATO, Javier de Jesus MENENDEZ DIAZ, Andrew CHIAPPETTA
  • Patent number: 10144940
    Abstract: The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: —one source of carbon, —protoporphyrin, —salts, —amino acids, —NAD or NADH, —vitamins, —means for regulating the pH, characterized in that said culture medium is chemically defined.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: December 4, 2018
    Assignee: Sanofi Pasteur
    Inventors: Jérome Le Hir, Pascal Loubiere, Fabien Barbirato, Nicholas Lindley
  • Publication number: 20170211111
    Abstract: The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: —one source of carbon, —protoporphyrin, —salts, —amino acids, —NAD or NADH, —vitamins, —means for regulating the pH, characterised in that said culture medium is chemically defined.
    Type: Application
    Filed: April 14, 2017
    Publication date: July 27, 2017
    Applicant: Sanofi Pasteur
    Inventors: Jérome Le Hir, Pascal Loubiere, Fabien Barbirato, Nicholas Lindley
  • Patent number: 9556464
    Abstract: The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: —one source of carbon, —protoporphyrin, —salts, —amino acids, —NAD or NADH, —vitamins, —means for regulating the pH, characterised in that said culture medium is chemically defined.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 31, 2017
    Assignee: Sanofi Pasteur
    Inventors: Jérome Le Hir, Pascal Loubiere, Fabien Barbirato, Nicholas Lindley
  • Publication number: 20150167036
    Abstract: The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: —one source of carbon, —protoporphyrin, —salts, —amino acids, —NAD or NADH, —vitamins, —means for regulating the pH, characterised in that said culture medium is chemically defined.
    Type: Application
    Filed: July 2, 2013
    Publication date: June 18, 2015
    Inventors: Jérome Le Hir, Pascal Loubiere, Fabien Barbirato, Nicholas Lindley